Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma

Li Ren Kong, Tuan Zea Tan, Weijie Richard Ong, Chonglei Bi, Hung Huynh, Soo C. Lee, Wee Joo Chng, Pieter J.a. Eichhorn, Boon Cher GohMolecular 2017 · DOI

TL;DR

This study reveals that belinostat, a histone deacetylase inhibitor, exerts its anti-cancer effects in lung squamous cell carcinoma (SCC) by hijacking the ubiquitin-proteasome system to degrade the MAPK pathway regulator SOS. This mechanism explains belinostat's efficacy, particularly in cisplatin-resistant SCC, and supports its combination with chemotherapy for improved treatment outcomes.

What Problem Does This Paper Address?

Lung squamous cell carcinoma (SCC) has lagged behind lung adenocarcinoma in benefiting from personalized therapies, largely due to a lack of clear molecular targets for small-molecule inhibitors. While histone deacetylase inhibitors (HDACis) like belinostat show promise, their effectiveness as single agents in solid tumors is often limited by toxicity and a lack of predictive biomarkers. This paper investigates the specific mechanisms by which belinostat exerts its anti-tumor effects in SCC, aiming to uncover how it can overcome resistance to existing treatments like cisplatin and identify potential therapeutic strategies.

Methods

The researchers employed a multi-pronged approach:

  • Cell Viability Assays: Standard MTS assays were used to determine the sensitivity of various lung SCC cell lines and normal lung fibroblasts to belinostat, establishing half-maximal inhibitory concentrations (IC50). Combination index (CI) analysis was performed to assess synergistic effects with cisplatin.
  • Phosphoproteomic Profiling: Phospho-MAPK arrays were used to identify key signaling pathways affected by belinostat treatment in SCC cells.
  • Western Blotting: This technique was extensively used to confirm changes in protein expression and phosphorylation levels of key signaling molecules (e.g., p-ERK1/2, p-p38, SOS1/2, PARP, cleaved caspase 3) in response to belinostat and/or cisplatin treatment.
  • Apoptosis Assays: Annexin-V/propidium iodide (PI) staining was employed to quantify the induction of apoptosis in treated cells.
  • Gene Expression Profiling: Affymetrix microarray analysis was conducted to identify global gene expression changes induced by belinostat.
  • RT-qPCR: Quantitative real-time PCR was used to validate mRNA expression levels of specific genes, particularly those involved in the ubiquitination pathway.
  • RNA Interference (siRNA): siRNA was used to specifically knock down the expression of FBXO3 and FBXW10 to investigate their role in belinostat's mechanism.
  • Proteasome Inhibition: Bortezomib, a proteasome inhibitor, was used to assess the role of proteasomal degradation in belinostat's effects.
  • Xenograft Studies: In vivo studies were conducted using SCID mice bearing Calu-1 xenografts to evaluate the therapeutic efficacy of belinostat and cisplatin, both alone and in combination.

Datasets

The study utilized publicly available gene expression data from the Gene Expression Omnibus (GEO) with accession ID GSE85979 for microarray analysis of belinostat-treated lung cancer cell lines. No new datasets or benchmarks were introduced.

Key Insights and Ideas

  • Differential Sensitivity to Belinostat: SCC cell lines exhibit varying sensitivities to belinostat, with some showing high sensitivity and others resistance. This suggests that intrinsic cellular factors influence response.
  • MAPK Pathway Suppression: Belinostat consistently suppresses the MAPK signaling pathway (ERK, p38, JNK) in sensitive SCC cells, which is a critical step in its cytotoxic mechanism.
  • SOS as a Key Target: The study identifies Son of Sevenless (SOS), an upstream regulator of the MAPK pathway, as a crucial target of belinostat. Belinostat leads to the downregulation of SOS protein levels.
  • Ubiquitin-Proteasome System Involvement: The core insight is that belinostat promotes the proteasomal degradation of SOS. This is mediated by the upregulation of F-box proteins FBXO3 and FBXW10, which act as components of E3 ubiquitin ligases.
  • Synergy with Cisplatin: Belinostat demonstrates significant synergistic cytotoxicity with cisplatin, particularly in cisplatin-resistant SCC cells. This synergy is linked to the combined suppression of MAPK signaling.
  • Epigenetic Regulation of Ubiquitination: Belinostat's ability to induce histone acetylation appears to be the upstream event that triggers the transcriptional upregulation of ubiquitin ligases, ultimately leading to SOS degradation.

Key Results

  • Belinostat showed differential IC50 values across SCC cell lines, with some being highly sensitive (<3 µM).
  • Belinostat treatment led to significant downregulation of MAPK pathway components (p-ERK1/2, p-p38) in sensitive SCC cells.
  • Apoptosis was induced by belinostat, evidenced by increased PARP cleavage and Annexin-V positive cells.
  • Belinostat treatment upregulated the expression of FBXO3 and FBXW10 mRNA and proteins.
  • The proteasomal degradation of SOS was confirmed by the rescue of SOS2 expression and p-ERK1/2 phosphorylation upon treatment with bortezomib or siRNA knockdown of FBXO3/FBXW10.
  • Combined treatment with belinostat and cisplatin showed synergistic cytotoxicity (CI < 0.8) in several SCC cell lines, with improved apoptosis induction.
  • Xenograft studies showed a lack of significant anti-tumor efficacy for single-agent belinostat or cisplatin at tolerable doses, suggesting the need for optimized delivery or combination strategies.

Limitations and Future Work

  • In Vivo Efficacy: The preclinical xenograft studies showed limited efficacy for belinostat alone or in combination with cisplatin at the tested doses. This highlights potential issues with belinostat's pharmacokinetics and suggests that further optimization of drug delivery and dosing strategies is crucial for clinical translation.
  • Clinical Biomarkers: While differential sensitivity to belinostat was observed, the paper notes the lack of a readily available biomarker to select patients who would benefit most from HDAC inhibitors, a challenge that remains for this class of drugs.
  • Crosstalk between HDAC Inhibition and Proteasome System: The authors suggest that further studies are needed to fully elucidate the complex crosstalk between HDAC inhibition and the proteasome system.
  • Combination Therapy Optimization: While synergy was demonstrated, further work is needed to optimize combination regimens, considering potential issues with prolonged bortezomib/belinostat exposure.
  • Mechanism of Resistance: The study identified belinostat-resistant cell lines (e.g., H226) where MAPK suppression and apoptosis induction were less pronounced. Understanding the mechanisms underlying this resistance could lead to more effective therapeutic strategies.

Summary updated

Abstract

There have been advances in personalized therapy directed by molecular profiles in lung adenocarcinoma, but not in lung squamous cell carcinoma (SCC). The lack of actionable driver oncogenes in SCC has restricted the use of small-molecule inhibitors. Here, we show that SCC cell lines displayed differential sensitivities to belinostat, a pan-histone deacetylase inhibitor. Phosphoproteomic analysis of belinostat-treated SCC cells revealed significant downregulation of the MAPK pathway, along with the induction of apoptosis. In cisplatin-resistant cells that demonstrated aberrant MAPK activation, combined treatment with belinostat significantly inhibited cisplatin-induced ERK phosphorylation and exhibited strong synergistic cytotoxicity. Furthermore, belinostat transcriptionally upregulated the F-box proteins FBXO3 and FBXW10, which directly targeted son of sevenless (SOS), an upstream regulator of the MAPK pathway, for proteasome-mediated degradation. Supporting this, suppression of SOS/ERK pathway by belinostat could be abrogated by inhibiting proteasomal activity either with bortezomib or with siRNA knockdown of FBXO3/FBXW10. Taken together, these preclinical data offer a novel understanding of the epigenetic mechanism by which belinostat exerts its cytotoxicity and supports the combination with cisplatin in clinical settings for chemorefractory SCC tumors.
BibTeX
@inproceedings{kong2017belinostat,
  author = {Li Ren Kong and Tuan Zea Tan and Weijie Richard Ong and Chonglei Bi and Hung Huynh and Soo C. Lee and Wee Joo Chng and Pieter J.A. Eichhorn and Boon Cher Goh},
  title = {{Belinostat exerts antitumor cytotoxicity through the ubiquitin‐proteasome pathway in lung squamous cell carcinoma}},
  booktitle = {Molecular},
  year = {2017},
  doi = {10.1002/1878-0261.12064},
}
Figure